Clinical Trial

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-26.
Status change: Not Yet Recruiting → Recruiting 2025-12-05
Trial Details
NCT Number NCT06856837
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions Metastatic Colorectal Cancer
Enrollment 140 participants
Start Date 2025-10-27
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-12